Efficacy and safety of low dose rivaroxaban in patients with coronary heart disease: a systematic review and meta-analysis

The mortality effects and risk-benefit profile of low dose rivaroxaban (2.5 mg twice daily) in patients with coronary heart disease are not completely understood. Five randomized controlled trials (26,110 patients) were selected using PubMed and Cochrane library till April 2019. The background antip...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:J Thromb Thrombolysis
Hauptverfasser: Khan, Safi U., Khan, Muhammad Zia, Asad, Zain Ul Abideen, Valavoor, Shahul, Khan, Muhammad Usman, Khan, Muhammad Shahzeb, Krupica, Troy, Alkhouli, Mohamad, Kaluski, Edo
Format: Artigo
Sprache:Inglês
Veröffentlicht: 2020
Schlagworte:
Article
Online Zugang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7554154/
https://ncbi.nlm.nih.gov/pubmed/32281069
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s11239-020-02114-7
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!

Ähnliche Einträge